- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06154252
Åpen studie for å evaluere sikkerheten og effekten av CABA-201 hos personer med aktiv idiopatisk inflammatorisk myopati
En fase 1/2, åpen studie for å evaluere sikkerheten og effekten av autologe CD19-spesifikke kimære antigenreseptor-T-celler (CABA-201) hos personer med aktiv idiopatisk inflammatorisk myopati
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Idiopathic inflammatory myopathies (IIMs, or myositis) are a group of rare autoimmune diseases characterized by inflammation and muscle weakness. Though the cause of IIM is not well understood, some subtypes of IIM, including dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy (IMNM), and juvenile idiopathic inflammatory myopathy (JIIM), are thought to involve B cells that cause the body to attack different tissues in the body. This study is being conducted to evaluate the safety and efficacy of an investigational cell therapy, CABA-201, that can be given to patients with DM, ASyS, IMNM, or JIIM who have active disease. A single dose of CABA-201 in combination with cyclophosphamide (CY) and fludarabine (FLU) will be evaluated.
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Cabaletta Bio
- Telefonnummer: 4444 267-759-3100
- E-post: clinicaltrials@cabalettabio.com
Studiesteder
-
-
California
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California Irvine - Accepting Adult Patients
-
Hovedetterforsker:
- Tahseen Mozaffar, MD
-
Ta kontakt med:
- Alpha Clinic
- Telefonnummer: 949-824-3990
- E-post: alphaclinic@uci.edu
-
San Francisco, California, Forente stater, 94158
- Rekruttering
- University of California, San Francisco Benioff Children's Hospital - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- Zilan Zheng
- Telefonnummer: 415-353-1301
- E-post: Zilan.Zheng@ucsf.edu
-
Hovedetterforsker:
- Susan Kim, MD, MMSc
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80046
- Rekruttering
- Children's Hospital Colorado - Accepting Juvenile Patients
-
Hovedetterforsker:
- Dr. Kentaro Yomogida, MD
-
Ta kontakt med:
- Callie Strini - Primary Clinical Research Coordinator
- Telefonnummer: 720-777-9845
- E-post: callie.strini@childrenscolorado.org
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224
- Rekruttering
- Mayo Clinic Florida - Accepting Adult Patients
-
Ta kontakt med:
- Gabrielle Pariseau
- Telefonnummer: 904-953-5549
- E-post: pariseau.gabrielle@mayo.edu
-
St. Petersburg, Florida, Forente stater, 33701
- Rekruttering
- Johns Hopkins All Children's Hospital - Accepting Juvenile Patients
-
Hovedetterforsker:
- Natalie Booth, DO
-
Ta kontakt med:
- Laura Escobar
- Telefonnummer: 727-767-2946
- E-post: llabarr2@jh.edu
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30032
- Rekruttering
- Emory University - Accepting Adult Patients
-
Ta kontakt med:
- John Varghese
- E-post: john.varghese@emory.edu
-
Hovedetterforsker:
- Prateek Chandrashekar Gandiga, MD, FACP
-
Atlanta, Georgia, Forente stater, 30029
- Rekruttering
- Children's Healthcare of Atlanta - Accepting Juvenile Patients
-
Hovedetterforsker:
- Shanmuganathan Chandrakasan, MD
-
Ta kontakt med:
- Judson Russell
- Telefonnummer: 404-785-7263
- E-post: Judson.russell@choa.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern Memorial Hospital - Accepting Adult Patients
-
Hovedetterforsker:
- Dr. George Georges, MD
-
Ta kontakt med:
- Kaitlin King
- Telefonnummer: 312-695-0990
- E-post: autoimmunesct@nm.org
-
Chicago, Illinois, Forente stater, 60637
- Rekruttering
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients
-
Hovedetterforsker:
- Dr. Iazsmin Ventura, MD
-
Ta kontakt med:
- Dr. Iazsmin Ventura, MD - Adult patient contact
- Telefonnummer: 773-702-6619
- E-post: iventura@uchicago.edu; Dequana.jones@bsd.uchicago.edu
-
Underetterforsker:
- Dr. Cuoghi Edens, MD, FAAP
-
Ta kontakt med:
- Dr. Cuoghi Edens, MD, FAAP - Juvenile patient contact
- E-post: cedens@bsd.uchicago.edu; Sydni.Hill@bsd.uchicago.edu
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- Tyler Sorensen
- Telefonnummer: 312-277-6828
- E-post: tsorensen@luriechildrens.org
-
Hovedetterforsker:
- Pooja N. Patel, DO
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- Rekruttering
- University of Kansas Medical Center - Accepting Adult Patients
-
Ta kontakt med:
- Samantha Colgan
- Telefonnummer: 913-945-9938
- E-post: scolgan@kumc.edu
-
-
Maryland
-
Bethesda, Maryland, Forente stater, 20892
- Rekruttering
- National Institutes of Health - Accepting Adult and Juvenile Patients
-
Ta kontakt med:
- Julie Thompson
- Telefonnummer: 301-480-3191
- E-post: Julie.thompson@nih.gov
-
Hovedetterforsker:
- Andrew Mammen, M.D., Ph.D.
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Boston Children's Hospital - Accepting Young Adults and Juvenile Patients
-
Hovedetterforsker:
- Susan Prockop, MD
-
Ta kontakt med:
- Kyle McBrearty
- Telefonnummer: 617-355-2780
- E-post: kyle.mcbrearty@childrens.harvard.edu
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48105
- Rekruttering
- University of Michigan - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- Abigail Whalen
- Telefonnummer: 734-615-4466
- E-post: abigaiwh@med.umich.edu
-
Hovedetterforsker:
- Dr. Jennifer Agrusa, MD
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55902
- Rekruttering
- Mayo Clinic - Accepting Adult Patients
-
Ta kontakt med:
- Bridget Neja
- Telefonnummer: 507-266-9150
- E-post: neja.bridget@mayo.edu
-
-
New York
-
New York, New York, Forente stater, 10021
- Rekruttering
- Hospital for Special Surgery - Accepting Adult and Juvenile Patients
-
Ta kontakt med:
- Janvi Bhatia
- Telefonnummer: 212-774-2123
- E-post: bhatiaj@hss.edu
-
Hovedetterforsker:
- David R. Fernandez, MD, PhD
-
New York, New York, Forente stater, 10021
- Rekruttering
- Memorial Sloan Kettering Cancer Center - Accepting Adult and Juvenile Patients
-
Hovedetterforsker:
- Jae Park, MD
-
Ta kontakt med:
- Atifah Osrat
- Telefonnummer: 646-608-2091
- E-post: osrata1@mskcc.org
-
The Bronx, New York, Forente stater, 10467
- Rekruttering
- Children's Hospital at Montefiore - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- Emily Gillies
- Telefonnummer: 718-696-2402
- E-post: egillies@montefiore.org
-
Hovedetterforsker:
- Dr. Dawn Wahezi, MD, MS
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill - Accepting Adult Patients
-
Hovedetterforsker:
- Saira Sheikh, MD
-
Ta kontakt med:
- Leah Luizza
- E-post: leah.luizza@med.unc.edu
-
Durham, North Carolina, Forente stater, 27710
- Rekruttering
- Duke University Medical Center - Accepting Young Adults and Juvenile Patients
-
Hovedetterforsker:
- Kaveh Ardalan, MD, MS
-
Ta kontakt med:
- Lynn Rodgers, MS
- Telefonnummer: 919-668-2953
- E-post: Lynn.rodgers@duke.edu
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- Rekruttering
- Oregon Health & Science University - Accepting Adult Patients
-
Ta kontakt med:
- Katie Lewis
- Telefonnummer: 503-908-9724
- E-post: lewiskat@ohsu.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19104
- Rekruttering
- Children's Hospital of Philadelphia - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- CARTintake@chop.edu
- E-post: CARTintake@chop.edu
-
Hovedetterforsker:
- Dr. Caitlin Elgarten, MD, MSCE
-
Pittsburgh, Pennsylvania, Forente stater, 15261
- Rekruttering
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients
-
Ta kontakt med:
- Carol Oriss
- E-post: orissca@upmc.edu
-
Hovedetterforsker:
- Jeremy Tilstra, MD
-
Pittsburgh, Pennsylvania, Forente stater, 15224
- Rekruttering
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients
-
Ta kontakt med:
- Vibha Chauhan, PhD
- Telefonnummer: 412-692-7924
- E-post: Vibha.chauhan@chp.edu
-
Hovedetterforsker:
- Kathryn Torok, MD
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Rekruttering
- Vanderbilt University Medical Center - Accepting Adult Patients
-
Ta kontakt med:
- Tofi Soneye
- Telefonnummer: 817-883-4730
- E-post: tofi.soneye@vumc.org
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- Rekruttering
- University of Texas Southwestern Medical Center - Accepting Juvenile Patients
-
Hovedetterforsker:
- Samuel John, MD
-
Ta kontakt med:
- Dr. Samuel John
- E-post: dtpteam@childrens.com
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- Houston Methodist Hospital - Accepting Adult Patients
-
Ta kontakt med:
- Amelia A. Nounes, MSN, RN, CCRP
- Telefonnummer: 346-356-3639
- E-post: aanounes@houstonmethodist.org
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- University of Texas MD Anderson Cancer Center - Accepting Adult Patients
-
Hovedetterforsker:
- Huifang (Linda) Lu, MD
-
Ta kontakt med:
- Christina Amos Briggs, BSN, RN
- Telefonnummer: 713-563-5076
- E-post: cbamos@mdanderson.org
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84113
- Rekruttering
- Primary Children's Hospital/University of Utah - Accepting Juvenile Patients
-
Ta kontakt med:
- Morgan Badgley - Research Coordinator
- Telefonnummer: 801-662-4812
- E-post: morgan.badgley@hsc.utah.edu
-
Hovedetterforsker:
- Aimee Ogden Hersh, MD
-
-
Washington
-
Seattle, Washington, Forente stater, 98105
- Rekruttering
- Seattle Children's Research Institute - Accepting Juvenile Patients
-
Ta kontakt med:
- Dr. Susan Shenoi, MD, MS
- Telefonnummer: 206-987-2193
- E-post: susan.shenoi@SeattleChildrens.org
-
Hovedetterforsker:
- Dr. Susan Shenoi, MD, MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, Forente stater, 53226
- Har ikke rekruttert ennå
- Children's Wisconsin Pediatric Rheumatology -Accepting Young Adult and Juvenile Patients
-
Hovedetterforsker:
- Sara Sabbagh, DO
-
Ta kontakt med:
- Erin Hammelev - Research Coordinator
- Telefonnummer: 414-337-7064
- E-post: ehammele@mcw.edu
-
-
-
-
-
Roma, Italia, 00165
- Rekruttering
- Ospedale Pediatrico Bambino Gesù - Accepting Young Adult and Juvenile Patients
-
Ta kontakt med:
- Dr. Marco Becilli
- Telefonnummer: +39 0668592739
- E-post: marco.becilli@opbg.net
-
Hovedetterforsker:
- Professor Franco Locatelli
-
-
-
-
-
London, Storbritannia, WC1N 3BG
- Rekruttering
- University College London Hospitals NHS Foundation Trust - Accepting Adult Patients
-
Ta kontakt med:
- Dr. Pedro Machado, FRCP, PhD
- Telefonnummer: 020 3456 7890
- E-post: uclh.car-ttrials@nhs.net
-
Hovedetterforsker:
- Dr. Pedro Machado, FRCP, PhD
-
London, Storbritannia, SE5 9RS
- Rekruttering
- Kings College Hospital NHS Foundation Trust - Accepting Adult Patients
-
Ta kontakt med:
- Rheumatology Research Team
- Telefonnummer: 0628 0207 848 0214
- E-post: Kch-tr.CRDresearch@nhs.net
-
Hovedetterforsker:
- Patrick Gordon, PhD, FRCP, MBBS
-
London, Storbritannia, WC1N 3JH
- Rekruttering
- Great Ormond Street Hospital for Children NHS Foundation Trust - Accepting Juvenile Patients
-
Ta kontakt med:
- Professor Despina Eleftheriou
- Telefonnummer: 020 7405 9200
- E-post: Despina.Eleftheriou@gosh.nhs.uk
-
Hovedetterforsker:
- Professor Despina Eleftheriou
-
Manchester, Storbritannia, M13 9WL
- Rekruttering
- Manchester Royal Infirmary - Accepting Adult Patients
-
Ta kontakt med:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
- Telefonnummer: 01612765052
- E-post: Eleni.Tholouli@mft.nhs.uk
-
Hovedetterforsker:
- Eleni Tholouli, MD, PhD, MRCP(UK), FRCPath
-
Salford, Storbritannia, M6 8HD
- Rekruttering
- Salford Royal Hospital - Accepting Adult Patients
-
Ta kontakt med:
- Michelle Beswick
- Telefonnummer: 07759 136787
- E-post: Rheumatology.Research@nca.nhs.uk
-
Hovedetterforsker:
- Hector Chinoy, PhD, FRCP, MSc, BMBS, BMedSci
-
-
-
-
-
Göttingen, Tyskland, 37075
- Har ikke rekruttert ennå
- Universitätsmedizin Göttingen - Accepting Adult Patients
-
Ta kontakt med:
- Dr. Jana Zschüntzsch
- E-post: j.zschuentzsch@med.uni-goettingen.de
-
Hovedetterforsker:
- Dr. Jana Zschüntzsch
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Adult Cohorts
Inclusion Criteria:
- Age ≥18 and ≤75
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Diagnosis of DM, ASyS, or IMNM
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated creatine kinase (CK), DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
- Presence of muscle weakness
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Juvenile Cohort
Inclusion Criteria:
- Age ≥6 and ≤17 years at enrollment
- A clinical diagnosis of IIM, based on the 2017 The European League Against Rheumatism/American College of Rheumatology classification criteria
- Evidence of active disease, despite prior or current treatment with standard of care treatments, as defined by the presence of elevated muscle enzymes, DM rash, or active disease on muscle biopsy, magnetic resonance imaging (MRI), or electromyography
Other protocol-defined criteria apply.
Exclusion Criteria:
- Contraindication to leukapheresis
- History of anaphylactic or severe systemic reaction to fludarabine, cyclophosphamide or any of their metabolites
- Active infection requiring medical intervention at screening
- Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, psychiatric, cardiac, neurological, or cerebral disease, including severe and uncontrolled infections, such as sepsis and opportunistic infections.
- Concomitant medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study, interfere with the assessment of the effects or safety of the investigational product or with the study procedures
- Significant lung or cardiac impairment
- Previous CAR T cell therapy
- Prior solid organ (heart, liver, kidney, lung) transplant or hematopoietic cell transplant
Other protocol-defined criteria apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: CABA-201 Phase 1/2
DM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM. ASyS Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with ASyS. IMNM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. JIIM Cohort: Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with JIIM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navn:
|
|
Eksperimentell: CABA-201 Phase 2b - Sub-study 1
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with DM and ASyS. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navn:
|
|
Eksperimentell: CABA-201 Phase 2b - Sub-study 2
Infusion of CABA-201 following preconditioning with fludarabine and cyclophosphamide in subjects with IMNM. |
Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Phase 1/2: Incidence and severity of adverse events (AEs)
Tidsramme: Up to 28 days after CABA-201 infusion
|
Incidence and severity of AEs |
Up to 28 days after CABA-201 infusion
|
|
Phase 2b Sub-study 1: Proportion of DM & ASyS subjects achieving at least a moderate Total Improvement Score (TIS) without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 16 weeks
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 16 weeks
|
|
Phase 2b Sub-study 2: Proportion of subjects with IMNM achieving at least a minimal TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Within 24 weeks
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Within 24 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events and laboratory abnormalities
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Incidence and severity of AEs, including changes in laboratory values and vital signs |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacodynamics (PD)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of B cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Pharmacokinetics (PK)
Tidsramme: Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
Levels of CABA-201-positive T cells in the blood |
Up to 156 weeks (Phase 1/2) and through 52 weeks (Sub-study 1 and 2)
|
|
Change in disease-related biomarkers of muscle inflammation
Tidsramme: Up to 156 weeks (Phase 1/2)
|
Levels of muscle enzymes (CK, LDH, AST, ALT, and aldolase) in serum |
Up to 156 weeks (Phase 1/2)
|
|
Change in autoantibody-related biomarkers
Tidsramme: Up to 156 weeks (Phase 1/2)
|
Levels of autoantibodies from the Myositis-Specific Autoantibody Panel (e.g., MDA-5, Jo-1, and HMGCR) in the serum |
Up to 156 weeks (Phase 1/2)
|
|
Proportion of DM subjects achieving at least a moderate TIS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with DM and ASyS without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 16 (Sub-study 1)
|
|
Proportion of DM and ASyS subjects achieving a major TIS response without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 16 (Sub-study 1)
|
≥60 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 16 (Sub-study 1)
|
|
Proportion of subjects with DM & ASyS achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Proportion of subjects with DM achieving moderate TIS without any immunomodulatory medications on no or low dose of steroids
Tidsramme: Week 52 (Sub-study 1)
|
≥40 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 1)
|
|
Mean change from baseline on the MMT-8 in subjects with IMNM without any immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 24 (Sub-study 2)
|
MMT-8 measures muscle strength on a scale ranging from 0 to 150 points, where higher scores reflect greater muscle strength |
Week 24 (Sub-study 2)
|
|
Proportion of subjects with IMNM achieving at least minimal TIS response without immunomodulatory medications and no or low dose of steroids
Tidsramme: Week 52 (Sub-study 2)
|
≥20 on the TIS, a composite measure ranging from 0 to 100, derived from six Core Set Measures, with higher scores indicating greater clinical improvement |
Week 52 (Sub-study 2)
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studiestol: Medical Director, Cabaletta Bio
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Muskel- og skjelettsykdommer
- Sykdommer i nervesystemet
- Muskelsykdommer
- Nevromuskulære sykdommer
- Bindevevssykdommer
- Sykdommer i immunsystemet
- Hudsykdommer
- Polymyositt
- Hud- og bindevevssykdommer
- Autoimmune sykdommer
- Dermatomyositt
- Myositt
- Organiske kjemikalier
- Hydrokarboner
- Fosforamid -sennep
- Nitrogen sennepsforbindelser
- Sennepsforbindelser
- Hydrokarboner, halogenert
- Fosforamider
- Organofosforforbindelser
- Cyklofosfamid
- fludarabin
Andre studie-ID-numre
- CAB-201-002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .